Palmitoyl Tetrapeptide-7 vs TB-500
A detailed comparison to help you understand the differences and choose the right peptide for your research goals.
Palmitoyl Tetrapeptide-7
Palmitoyl Tetrapeptide-7 is an anti-inflammatory peptide that reduces IL-6 secretion. Combined with Palmitoyl Tripeptide-1, it forms Matrixyl 3000, addressing both collagen production and inflammation.
Full details →TB-500
Thymosin Beta-4 (TB-500) is a naturally occurring peptide present in almost all human and animal cells. It plays a crucial role in tissue repair and regeneration.
Full details →Side-by-Side Comparison
| Aspect | Palmitoyl Tetrapeptide-7 | TB-500 |
|---|---|---|
| Mechanism | Suppresses interleukin-6 (IL-6) production, reducing inflammation that contributes to skin aging. The anti-inflammatory effect complements collagen-stimulating peptides. | TB-500 promotes cell migration and differentiation, regulates actin (a cell-building protein), and reduces inflammation. It supports the formation of new blood vessels and wound healing. |
| Typical Dosage | Topical: Usually combined with Palmitoyl Tripeptide-1 at similar concentrations (2-4%) in the Matrixyl 3000 complex. | Research protocols typically use 2-2.5mg twice weekly during the loading phase, followed by maintenance dosing of 2mg every 2 weeks. |
| Administration | Topical application with other anti-aging actives. The palmitoyl group enhances delivery into the skin. | Administered via subcutaneous or intramuscular injection. Some protocols suggest injection near injury sites. |
| Side Effects | Excellent tolerability profile. Anti-inflammatory properties may actually soothe sensitive skin. | May cause temporary fatigue, headache, or localized irritation at injection sites. |
| Best For |